Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.45 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | FPR2 | P25090 | 4/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13428258 | 0.99 | USP2 (0.53) | USP2MEN1POLBPPARGBLM | |
| SCHEMBL18350813 | 0.99 | USP2 (0.53) | USP2MEN1POLBPPARGBLM | |
| SCHEMBL14667860 | 0.99 | USP2 (0.53) | USP2MEN1POLBPPARGBLM | |
| Hydrochloric Acid SCHEMBL29539118 | 0.97 | USP2 (0.54) | USP2MEN1POLBPPARGBLM | |
| Perchlorate SCHEMBL29352706 | 0.96 | USP2 (0.53) | USP2MEN1POLBPPARGBLM | |
| SCHEMBL22292200 | 0.96 | USP2 (0.55) | USP2MEN1POLBPPARGBLM | |
| SCHEMBL17693120 | 0.94 | USP2 (0.53) | USP2MEN1POLBPPARGBLM | |
| SCHEMBL17693127 | 0.94 | USP2 (0.53) | USP2MEN1POLBPPARGBLM | |
| SCHEMBL10124264 | 0.93 | USP2 (0.56) | USP2MEN1POLBPPARGBLM | |
| SCHEMBL17693122 | 0.93 | MEN1 (0.50) | USP2MEN1POLBPPARGBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137252-A1 | HIGH THROUGHPUT METHOD FOR SCREENING LIPID NANOPARTICLE EFFICACY AND CYTOTOXICITY | CZ BIOHUB SF, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| US-20240180880-A1 | METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERS | Epizyme, Inc. | 2024-06-06 | — | — | US | claimed |
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2024-05-30 | — | — | US | claimed |
| CN-118021814-A | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2024-05-14 | — | — | CN | claimed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | claimed |
| CN-110068529-B | Characterization method of outer vesicle | 中国科学院深圳先进技术研究院 | 2023-06-23 | — | — | CN | claimed |
| US-12569508-B2 | Antimicrobial compositions and methods of use | UNIV SOUTH AUSTRALIA (AU) | 2026-03-10 | — | — | US | disclosed |
| US-20250350796-A1 | METHODS AND APPARATUS TO DEDUPLICATE AUDIENCE ESTIMATES FROM MULTIPLE COMPUTER SOURCES | NIELSEN CO US LLC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-3791863-B1 | PROCESS FOR THE PRODUCTION OF HYBRIDOSOMES | ANJARIUM BIOSCIENCES AG (CH) | 2025-09-10 | — | — | EP | disclosed |
| US-12375761-B2 | Methods and apparatus to deduplicate audience estimates from multiple computer sources | THE NIELSEN COMPANY (US), LLC (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025137252-A1 | HIGH THROUGHPUT METHOD FOR SCREENING LIPID NANOPARTICLE EFFICACY AND CYTOTOXICITY | CZ BIOHUB SF, LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12268676-B2 | Antiviral applications of picolinic acid and its derivatives | INDIAN INSTITUTE OF SCIENCE (IN) | 2025-04-08 | — | — | US | disclosed |
| EP-4497284-A1 | SIDELINK ANCHOR DEVICE MANAGEMENT | Lenovo (Singapore) Pte. Ltd. (SG) | 2025-01-29 | — | — | EP | disclosed |
| WO-2022218487-A1 | A VAGINAL CONTRACEPTIVE COMPOSITION FOR REINFORCEMENT OF THE CERVICAL MUCUS BARRIER PROPERTIES | CIRQLE BIOMEDICAL CONTRACEPTION ApS (DK) | 2022-10-20 | — | — | WO | disclosed |
| CN-217237187-U | Electric control valve simulation detection structure | 四川红华实业有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220257604-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-18 | — | — | US | disclosed |
| WO-2022157656-A1 | ANTIVIRAL APPLICATIONS OF PICOLINIC ACID AND ITS DERIVATIVES | INDIAN INSTITUTE OF SCIENCE (IN) | 2022-07-28 | — | — | WO | disclosed |
| US-20220226292-A1 | Antiviral Applications of Picolinic Acid and its Derivatives | INDIAN INSTITUTE OF SCIENCE (IN) | 2022-07-21 | — | — | US | disclosed |
| WO-2022109684-A1 | ORAL THERAPEUTIC DELIVERY | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022077060-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569508-B2 | Antimicrobial compositions and methods of use | PCTP, PYCARD, PLIN3 | CHRM1 3835/4885SLC6A2 4071/4885SLC6A3 3923/4885 |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | CHRM1 4444/4885SLC6A2 941/4885SLC6A3 2300/4885 |
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | CHRM1 4725/4885SLC6A2 651/4885SLC6A3 2276/4885 |
| US-20240180880-A1 | METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERS | BHMT2, BHMT, SHMT2 | CHRM1 4289/4885SLC6A2 95/4885SLC6A3 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.